BRD4 inhibitor

DRUG CLASS:

BRD4 inhibitor

News alerts, weekly reports and conference planners

Related drugs:

MLL translocation	Acute Myelogenous Leukemia	MLL translocation	Acute Myelogenous Leukemia	OTX015 Resistant: C3 – Early Trials OTX015 Resistant : C3	OTX015 Resistant: C3 – Early Trials OTX015 Resistant : C3
SPI1 deletion	Acute Myelogenous Leukemia	SPI1 deletion	Acute Myelogenous Leukemia	OTX015 Sensitive: C3 – Early Trials OTX015 Sensitive : C3	OTX015 Sensitive: C3 – Early Trials OTX015 Sensitive : C3
MTHFR underexpression	Acute Myelogenous Leukemia	MTHFR underexpression	Acute Myelogenous Leukemia	OTX015 Sensitive: C3 – Early Trials OTX015 Sensitive : C3	OTX015 Sensitive: C3 – Early Trials OTX015 Sensitive : C3
KMT2A rearrangement	Acute Myelogenous Leukemia	KMT2A rearrangement	Acute Myelogenous Leukemia	venetoclax + sunitinib + I-BET151 Sensitive: C3 – Early Trials venetoclax + sunitinib + I-BET151 Sensitive : C3	venetoclax + sunitinib + I-BET151 Sensitive: C3 – Early Trials venetoclax + sunitinib + I-BET151 Sensitive : C3
MYCN amplification	Neuroblastoma	MYCN amplification	Neuroblastoma	OTX015 Sensitive: D – Preclinical OTX015 Sensitive : D	OTX015 Sensitive: D – Preclinical OTX015 Sensitive : D
HUWE1 mutation	Cervical Cancer	HUWE1 mutation	Cervical Cancer	GS-626510 Sensitive: D – Preclinical GS-626510 Sensitive : D	GS-626510 Sensitive: D – Preclinical GS-626510 Sensitive : D
MYC overexpression	Cervical Cancer	MYC overexpression	Cervical Cancer	GS-626510 Sensitive: D – Preclinical GS-626510 Sensitive : D	GS-626510 Sensitive: D – Preclinical GS-626510 Sensitive : D
MYCL overexpression	Multiple Myeloma	MYCL overexpression	Multiple Myeloma	I-BET151 Sensitive: D – Preclinical I-BET151 Sensitive : D	I-BET151 Sensitive: D – Preclinical I-BET151 Sensitive : D
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	quizartinib + PLX51107 Sensitive: D – Preclinical quizartinib + PLX51107 Sensitive : D	quizartinib + PLX51107 Sensitive: D – Preclinical quizartinib + PLX51107 Sensitive : D
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	PLX51107 Sensitive: D – Preclinical PLX51107 Sensitive : D	PLX51107 Sensitive: D – Preclinical PLX51107 Sensitive : D
MUS81 overexpression	Gastric Cancer	MUS81 overexpression	Gastric Cancer	SRA515 Sensitive: D – Preclinical SRA515 Sensitive : D	SRA515 Sensitive: D – Preclinical SRA515 Sensitive : D
CCNA2 expression	Gastric Cancer	CCNA2 expression	Gastric Cancer	BI2536 Sensitive: D – Preclinical BI2536 Sensitive : D	BI2536 Sensitive: D – Preclinical BI2536 Sensitive : D
TERT rearrangement	Neuroblastoma	TERT rearrangement	Neuroblastoma	OTX015 Sensitive: D – Preclinical OTX015 Sensitive : D	OTX015 Sensitive: D – Preclinical OTX015 Sensitive : D
FGFR1 amplification	Lung Cancer	FGFR1 amplification	Lung Cancer	ABSK091 + NBL-001 + BI2536 Sensitive: D – Preclinical ABSK091 + NBL-001 + BI2536 Sensitive : D	ABSK091 + NBL-001 + BI2536 Sensitive: D – Preclinical ABSK091 + NBL-001 + BI2536 Sensitive : D
FGFR1 amplification	Lung Cancer	FGFR1 amplification	Lung Cancer	NBL-001 + BI2536 Sensitive: D – Preclinical NBL-001 + BI2536 Sensitive : D	NBL-001 + BI2536 Sensitive: D – Preclinical NBL-001 + BI2536 Sensitive : D
BTK C481S	Mantle Cell Lymphoma	BTK C481S	Mantle Cell Lymphoma	SRX3262 Sensitive: D – Preclinical SRX3262 Sensitive : D	SRX3262 Sensitive: D – Preclinical SRX3262 Sensitive : D
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	KO-539 + OTX015 Sensitive: D – Preclinical KO-539 + OTX015 Sensitive : D	KO-539 + OTX015 Sensitive: D – Preclinical KO-539 + OTX015 Sensitive : D
MLL mutation	Acute Myelogenous Leukemia	MLL mutation	Acute Myelogenous Leukemia	KO-539 + OTX015 Sensitive: D – Preclinical KO-539 + OTX015 Sensitive : D	KO-539 + OTX015 Sensitive: D – Preclinical KO-539 + OTX015 Sensitive : D
RB1 deletion	Ovarian Cancer	RB1 deletion	Ovarian Cancer	SRA515 Sensitive: D – Preclinical SRA515 Sensitive : D	SRA515 Sensitive: D – Preclinical SRA515 Sensitive : D
RB1 deletion	Ovarian Cancer	RB1 deletion	Ovarian Cancer	palbociclib + SRA515 Sensitive: D – Preclinical palbociclib + SRA515 Sensitive : D	palbociclib + SRA515 Sensitive: D – Preclinical palbociclib + SRA515 Sensitive : D
ARID1A mutation	Bladder Cancer	ARID1A mutation	Bladder Cancer	OTX015 Sensitive: D – Preclinical OTX015 Sensitive : D	OTX015 Sensitive: D – Preclinical OTX015 Sensitive : D
Chr inv(3)t(3;3) + MECOM overexpression	Acute Myelogenous Leukemia	Chr inv(3)t(3;3) + MECOM overexpression	Acute Myelogenous Leukemia	OTX015 + BC2059 Sensitive: D – Preclinical OTX015 + BC2059 Sensitive : D	OTX015 + BC2059 Sensitive: D – Preclinical OTX015 + BC2059 Sensitive : D
FLT3-ITD mutation + NPM1 mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation + NPM1 mutation	Acute Myelogenous Leukemia	OTX015 + FHD-286 Sensitive: D – Preclinical OTX015 + FHD-286 Sensitive : D	OTX015 + FHD-286 Sensitive: D – Preclinical OTX015 + FHD-286 Sensitive : D

BRD4 inhibitor

BRD4 inhibitor

Associations(23)

Associations
(23)